For the Inventor, By the Inventor

Enter assignee name

Geneva, Switzerland

Addex Pharma, S.a.

USPTO Granted Patents = 37

CIPO Patents = 34

EPO Patents = 30

Forward Citations = 173

Loading Chart...

Loading Chart...

155 inventors (with patents filed for the assignee):

Andrés Avelino Trabanco-Suárez (21 out of 53 patents)

Jose Maria Cid-Nunez (20 out of 21 patents)

Gregor James MacDonald (17 out of 56 patents)

4. Guillaume Albert Jacques Duvey (10 out of 11 patents)

5. Robert Johannes Lutjens (7 out of 8 patents)

6. Gary John Tresadern (5 out of 19 patents)

7. Juan Antonio Vega Ramiro (5 out of 10 patents)

8. Christelle Boléa (5 out of 5 patents)

9. Anne-Sophie Bessis (5 out of 6 patents)

10. Mark Epping-Jordan (5 out of 5 patents)

11. Jean-Philippe Rocher (5 out of 6 patents)

12. Terry Patrick Finn (4 out of 9 patents)

13. Daniel Oehlrich (4 out of 16 patents)

14. Christelle Bolea (4 out of 6 patents)

15. Beatrice Bonnet (4 out of 4 patents)

37 patents: Sort by Forward Citations

1. 10071095 - 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders (2018-09-11),

2. 9938270 - Mono-phosphate salt of 6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2A]pyridine (dipraglurant) and polymorphs thereof as negative allosteric modulator of MGLU5 receptor (2018-04-10),

3. 9765091 - Tetrahydropyrazolo [3,4-b] azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors (2017-09-19),

4. 9737533 - 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders (2017-08-22),

5. 9266834 - 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors (2016-02-23),

6. 9226930 - 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders (2016-01-05),

7. 9132122 - [object Object] (2015-09-15),

8. 9114138 - [object Object] (2015-08-25),

9. 9085577 - 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors (2015-07-21),

10. 9073907 - Thiazoles derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors (2015-07-07),

11. 9067891 - 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors (2015-06-30),

12. 8946205 - 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors (2015-02-03),

13. 8937060 - 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders (2015-01-20),

14. 8906939 - 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives (2014-12-09),

15. 8883826 - Alkynyl derivatives as modulators of metabotropic glutamate receptors (2014-11-11),

Addex Pharma, S.A. is a pharmaceutical company specializing in the discovery and development of innovative small molecule drugs for unmet medical needs. With a focus on neurological disorders, the company utilizes its proprietary allosteric modulation platform to target G-protein coupled receptors (GPCRs). Addex Pharma aims to deliver breakthroughs in areas such as Parkinson's disease, epilepsy, and addiction disorders.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

37 Patents

#11 in Geneva

#390 in Switzerland

#17,697 in the World

Geneva, Switzerland

Addex Pharma, S.a.

Forward Citations = 173

155 inventors:

Andrés Avelino Trabanco-Suárez (21 out of 53 patents)

Jose Maria Cid-Nunez (20 out of 21 patents)

Gregor James MacDonald (17 out of 56 patents)

4. Guillaume Albert Jacques Duvey (10 out of 11 patents)

5. Robert Johannes Lutjens (7 out of 8 patents)

Please report any incorrect information to support@idiyas.com

Loading…